Cochrane Abstracts
Vascular‐endothelial‐growth‐factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Vascular‐endothelial‐growth‐factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435567/all/Vascular‐endothelial‐growth‐factor__VEGF__targeting_therapies_for_endocrine_refractory_or_resistant_metastatic_breast_cancer.
Vascular‐endothelial‐growth‐factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435567/all/Vascular‐endothelial‐growth‐factor__VEGF__targeting_therapies_for_endocrine_refractory_or_resistant_metastatic_breast_cancer. Accessed January 13, 2025.
Vascular‐endothelial‐growth‐factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435567/all/Vascular‐endothelial‐growth‐factor__VEGF__targeting_therapies_for_endocrine_refractory_or_resistant_metastatic_breast_cancer
Vascular‐endothelial‐growth‐factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2025 January 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435567/all/Vascular‐endothelial‐growth‐factor__VEGF__targeting_therapies_for_endocrine_refractory_or_resistant_metastatic_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vascular‐endothelial‐growth‐factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
ID - 435567
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435567/all/Vascular‐endothelial‐growth‐factor__VEGF__targeting_therapies_for_endocrine_refractory_or_resistant_metastatic_breast_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
